)
NEWS
Media Contacts:
Canada
Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com
CSL Seqirus news releases
CSL Seqirus news releases
New Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake
Despite high burden of disease, influenza continues to suffer from perceived lack of risk, contributing to low vaccine uptake among parents and Canadian adults
Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans
Health Canada’s Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic Partner
Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020
Absolute Efficacy of Cell-Based Influenza Vaccines in Children Aged 2 to 18 Years, Impact of COVID-19 on Canadians’ Views of Influenza, Among Data Being Presented
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains1.